Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy

M. Colecchia, B. Frigo, C. Del Boca, A. Guardamagna, A. Zucchi, D. Colloi, O. Leopardi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Aims - Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy. Methods - Twenty six formalin fixed, paraffin wax embedded core biopsies and corresponding prostatectomy specimens, excised after three months of combined endocrine therapy, were analysed for the presence of apoptotic cells by the terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL) method, and for p53 and bc1-2 overexpression by immunohistochemistry. Results - All 26 adenocarcinomas were clinically localised at diagnosis. In biopsies performed before combined endocrine therapy, the apoptotic indices varied between 0.09% and 1.73%, while the tumour grade fell between Gleason score 1 and 8. The mean (SD) apoptotic count pretherapy was 0.71% (0.50). There was a significant association between elevated apoptotic counts and higher Gleason scores in the biopsies (p = 0.005). After three months of therapy, the percentage of apoptotic tumour cells increased independently of tumour stage, while a significant association with Gleason grade was found (p = 0.0018) and all the tumours had Gleason scores of <7. In eight cases the apoptotic index was more than twice its pretherapy value. The remaining tumours showed less of an increase in the apoptotic index (five cases) or a reduction in the percentage of apoptotic cells. The overall moderate increase in apoptotic index after combined endocrine therapy was not statistically significant (p = 0.8). Immunoreactivity to p53 was absent in all cases, before and after therapy, while a slight increase in the number of cells overexpressing bc1-2 was observed in five of the 13 tumours (38.1%) with reduced apoptotic indices after therapy. Conclusions - After three months of combined endocrine treatment a minority of clinically localised prostate neoplasms showed regressive epithelial alterations, associated with an increase in apoptotic tumour cells; an increase in cells overexpressing bc1-2 was observed in five of the 13 tumours with reduced apoptotic indices.

Original languageEnglish
Pages (from-to)384-388
Number of pages5
JournalJournal of Clinical Pathology
Volume50
Issue number5
Publication statusPublished - 1997

Fingerprint

Biotin
Transferases
Prostatic Neoplasms
Apoptosis
Neoplasms
Neoplasm Grading
Therapeutics
Biopsy
DNA Nucleotidylexotransferase
Waxes
Prostatectomy
Paraffin
Formaldehyde
Adenocarcinoma
Cell Count
Immunohistochemistry

Keywords

  • Apoptosis
  • Nick end labelling
  • Prostatic cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. / Colecchia, M.; Frigo, B.; Del Boca, C.; Guardamagna, A.; Zucchi, A.; Colloi, D.; Leopardi, O.

In: Journal of Clinical Pathology, Vol. 50, No. 5, 1997, p. 384-388.

Research output: Contribution to journalArticle

Colecchia, M, Frigo, B, Del Boca, C, Guardamagna, A, Zucchi, A, Colloi, D & Leopardi, O 1997, 'Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy', Journal of Clinical Pathology, vol. 50, no. 5, pp. 384-388.
Colecchia, M. ; Frigo, B. ; Del Boca, C. ; Guardamagna, A. ; Zucchi, A. ; Colloi, D. ; Leopardi, O. / Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. In: Journal of Clinical Pathology. 1997 ; Vol. 50, No. 5. pp. 384-388.
@article{685c25148c924503bb8ca6de7a1d10ef,
title = "Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy",
abstract = "Aims - Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy. Methods - Twenty six formalin fixed, paraffin wax embedded core biopsies and corresponding prostatectomy specimens, excised after three months of combined endocrine therapy, were analysed for the presence of apoptotic cells by the terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL) method, and for p53 and bc1-2 overexpression by immunohistochemistry. Results - All 26 adenocarcinomas were clinically localised at diagnosis. In biopsies performed before combined endocrine therapy, the apoptotic indices varied between 0.09{\%} and 1.73{\%}, while the tumour grade fell between Gleason score 1 and 8. The mean (SD) apoptotic count pretherapy was 0.71{\%} (0.50). There was a significant association between elevated apoptotic counts and higher Gleason scores in the biopsies (p = 0.005). After three months of therapy, the percentage of apoptotic tumour cells increased independently of tumour stage, while a significant association with Gleason grade was found (p = 0.0018) and all the tumours had Gleason scores of <7. In eight cases the apoptotic index was more than twice its pretherapy value. The remaining tumours showed less of an increase in the apoptotic index (five cases) or a reduction in the percentage of apoptotic cells. The overall moderate increase in apoptotic index after combined endocrine therapy was not statistically significant (p = 0.8). Immunoreactivity to p53 was absent in all cases, before and after therapy, while a slight increase in the number of cells overexpressing bc1-2 was observed in five of the 13 tumours (38.1{\%}) with reduced apoptotic indices after therapy. Conclusions - After three months of combined endocrine treatment a minority of clinically localised prostate neoplasms showed regressive epithelial alterations, associated with an increase in apoptotic tumour cells; an increase in cells overexpressing bc1-2 was observed in five of the 13 tumours with reduced apoptotic indices.",
keywords = "Apoptosis, Nick end labelling, Prostatic cancer",
author = "M. Colecchia and B. Frigo and {Del Boca}, C. and A. Guardamagna and A. Zucchi and D. Colloi and O. Leopardi",
year = "1997",
language = "English",
volume = "50",
pages = "384--388",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy

AU - Colecchia, M.

AU - Frigo, B.

AU - Del Boca, C.

AU - Guardamagna, A.

AU - Zucchi, A.

AU - Colloi, D.

AU - Leopardi, O.

PY - 1997

Y1 - 1997

N2 - Aims - Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy. Methods - Twenty six formalin fixed, paraffin wax embedded core biopsies and corresponding prostatectomy specimens, excised after three months of combined endocrine therapy, were analysed for the presence of apoptotic cells by the terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL) method, and for p53 and bc1-2 overexpression by immunohistochemistry. Results - All 26 adenocarcinomas were clinically localised at diagnosis. In biopsies performed before combined endocrine therapy, the apoptotic indices varied between 0.09% and 1.73%, while the tumour grade fell between Gleason score 1 and 8. The mean (SD) apoptotic count pretherapy was 0.71% (0.50). There was a significant association between elevated apoptotic counts and higher Gleason scores in the biopsies (p = 0.005). After three months of therapy, the percentage of apoptotic tumour cells increased independently of tumour stage, while a significant association with Gleason grade was found (p = 0.0018) and all the tumours had Gleason scores of <7. In eight cases the apoptotic index was more than twice its pretherapy value. The remaining tumours showed less of an increase in the apoptotic index (five cases) or a reduction in the percentage of apoptotic cells. The overall moderate increase in apoptotic index after combined endocrine therapy was not statistically significant (p = 0.8). Immunoreactivity to p53 was absent in all cases, before and after therapy, while a slight increase in the number of cells overexpressing bc1-2 was observed in five of the 13 tumours (38.1%) with reduced apoptotic indices after therapy. Conclusions - After three months of combined endocrine treatment a minority of clinically localised prostate neoplasms showed regressive epithelial alterations, associated with an increase in apoptotic tumour cells; an increase in cells overexpressing bc1-2 was observed in five of the 13 tumours with reduced apoptotic indices.

AB - Aims - Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy. Methods - Twenty six formalin fixed, paraffin wax embedded core biopsies and corresponding prostatectomy specimens, excised after three months of combined endocrine therapy, were analysed for the presence of apoptotic cells by the terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL) method, and for p53 and bc1-2 overexpression by immunohistochemistry. Results - All 26 adenocarcinomas were clinically localised at diagnosis. In biopsies performed before combined endocrine therapy, the apoptotic indices varied between 0.09% and 1.73%, while the tumour grade fell between Gleason score 1 and 8. The mean (SD) apoptotic count pretherapy was 0.71% (0.50). There was a significant association between elevated apoptotic counts and higher Gleason scores in the biopsies (p = 0.005). After three months of therapy, the percentage of apoptotic tumour cells increased independently of tumour stage, while a significant association with Gleason grade was found (p = 0.0018) and all the tumours had Gleason scores of <7. In eight cases the apoptotic index was more than twice its pretherapy value. The remaining tumours showed less of an increase in the apoptotic index (five cases) or a reduction in the percentage of apoptotic cells. The overall moderate increase in apoptotic index after combined endocrine therapy was not statistically significant (p = 0.8). Immunoreactivity to p53 was absent in all cases, before and after therapy, while a slight increase in the number of cells overexpressing bc1-2 was observed in five of the 13 tumours (38.1%) with reduced apoptotic indices after therapy. Conclusions - After three months of combined endocrine treatment a minority of clinically localised prostate neoplasms showed regressive epithelial alterations, associated with an increase in apoptotic tumour cells; an increase in cells overexpressing bc1-2 was observed in five of the 13 tumours with reduced apoptotic indices.

KW - Apoptosis

KW - Nick end labelling

KW - Prostatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0030912982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030912982&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 384

EP - 388

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 5

ER -